Infinimmune Announces Partnership with Grid Therapeutics to Conduct Deep Sequencing of B Cells for Oncology Drug Discovery

Our round-up of venture capital financings in biotech this week features Vaderis, Aureka, Epicrispr, Infinimmune, and Boulevard Bio.

Many startups raise seed money from VCs and don't go on to get any more investment. Here's how one Alameda company beat the odds.

The funds will be used to advance two complementary eczema programs that leverage millions of screened human memory B cells and protein language models to deliver more potent and longer‑acting…

Backed by a $75m raise, Infinimmune targets cytokine cascades in skin aging – with an eye on systemic immunosenescence.

Immunology startup Infinimmune is developing antibody drugs with potential advantages over traditional monoclonal antibodies. The Series A financing will support two lead programs entering the clinic in atopic dermatitis. The post Infinimmune Secures $75M for a More Human Approach to Developing Better Antibody Drugs appeared first on MedCity News .

KBI Biopharma joins forces with Infinimmune to manufacture the latter’s monoclonal antibody for atopic dermatitis, IFX-101.

Reported Thursday, Sep 18 - 8:03am EDT (TheFly subscription required to read more.)

Deal worth up to $838 million suggests Big Pharma is looking for faster, more human-first ways to build medicines that shape healthier aging.

KBI Biopharma joins forces with Infinimmune to manufacture the latter’s monoclonal antibody for atopic dermatitis, IFX-101.